CC vs. ASIX, CE, DD, DOW, EMN, HUN, NTR, OLN, TKR, and TROX
Should you be buying Chemours stock or one of its competitors? The main competitors of Chemours include AdvanSix (ASIX), Celanese (CE), DuPont de Nemours (DD), DOW (DOW), Eastman Chemical (EMN), Huntsman (HUN), Nutrien (NTR), Olin (OLN), Timken (TKR), and Tronox (TROX).
Chemours vs. Its Competitors
Chemours (NYSE:CC) and AdvanSix (NYSE:ASIX) are both basic materials companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, dividends, valuation, institutional ownership, profitability and risk.
Chemours pays an annual dividend of $0.35 per share and has a dividend yield of 2.3%. AdvanSix pays an annual dividend of $0.64 per share and has a dividend yield of 3.1%. Chemours pays out -12.5% of its earnings in the form of a dividend. AdvanSix pays out 22.5% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. AdvanSix has increased its dividend for 2 consecutive years. AdvanSix is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.
AdvanSix has a net margin of 5.10% compared to Chemours' net margin of -7.19%. Chemours' return on equity of 35.14% beat AdvanSix's return on equity.
Chemours has a beta of 1.61, suggesting that its share price is 61% more volatile than the S&P 500. Comparatively, AdvanSix has a beta of 1.6, suggesting that its share price is 60% more volatile than the S&P 500.
Chemours currently has a consensus price target of $17.38, suggesting a potential upside of 13.24%. AdvanSix has a consensus price target of $33.50, suggesting a potential upside of 60.53%. Given AdvanSix's stronger consensus rating and higher probable upside, analysts plainly believe AdvanSix is more favorable than Chemours.
In the previous week, Chemours had 18 more articles in the media than AdvanSix. MarketBeat recorded 18 mentions for Chemours and 0 mentions for AdvanSix. AdvanSix's average media sentiment score of 1.68 beat Chemours' score of 0.81 indicating that AdvanSix is being referred to more favorably in the news media.
76.3% of Chemours shares are held by institutional investors. Comparatively, 86.4% of AdvanSix shares are held by institutional investors. 0.5% of Chemours shares are held by insiders. Comparatively, 5.6% of AdvanSix shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Chemours has higher revenue and earnings than AdvanSix. Chemours is trading at a lower price-to-earnings ratio than AdvanSix, indicating that it is currently the more affordable of the two stocks.
Summary
AdvanSix beats Chemours on 11 of the 19 factors compared between the two stocks.
Get Chemours News Delivered to You Automatically
Sign up to receive the latest news and ratings for CC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding CC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Chemours Competitors List
Related Companies and Tools
This page (NYSE:CC) was last updated on 8/22/2025 by MarketBeat.com Staff
MarketBeat All Access